[A17-47] Osimertinib (lung cancer) - Addendum to Commission A17-20
Last updated 19.10.2017
Commission awarded on 12.09.2017 by the Federal Joint Committee (G-BA).
Advanced NSCLC (lung cancer) with T790M mutation after pretreatment with EGFR-TKI
Unchanged hint of non-quantifiable, at least considerable added benefit versus cisplatin + pemetrexed
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.